sponsored byAAAS Golden Fund

EurekAlert!, a service of AAAS
Home About us
Advanced Search
28-Aug-2016 18:39
US Eastern Time

Username:

Password:

Register

Forgot Password?

Press Releases

Breaking News

Science Business

Grants, Awards, Books

Meetings

Multimedia

Science Agencies
on EurekAlert!

US Department of Energy

US National Institutes of Health

US National Science Foundation

Calendar

Submit a Calendar Item

Subscribe/Sponsor

Links & Resources

Portals

RSS Feeds

Accessibility Option On

Options

Portal Home

Glossary

Background Articles

Research Papers

Meetings

Links & Resources

Disease in the Developing World

News Releases

Key: Meeting M      Journal J      Funder F

Showing releases 251-275 out of 1298.

<< < 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 > >>

Public Release: 26-Apr-2016
PLOS ONE
The $60 billion question -- can we prevent norovirus?
Each year, norovirus causes over 200,000 deaths and a global economic burden of $60 billion. In a new PLOS Collection -- 'The Global Burden of Norovirus & Prospects for Vaccine Development' -- global norovirus experts fill critical knowledge gaps and provide key information to further development of a much-needed vaccine.
US Centers for Disease Control and Prevention, Bill and Melinda Gates Foundation

Contact: Nathaniel Gore
collections@plos.org
PLOS

Public Release: 25-Apr-2016
PLOS ONE
Vitamin D insufficiency, low rate of DNA methylation in black teens may increase disease risk
Low levels of vitamin D in black teens correlates with low activity of a major mechanism for controlling gene expression that may increase their risk of cancer and other disease, researchers report.
American Heart Association

Contact: Toni Baker
tbaker@augusta.edu
706-721-4421
Medical College of Georgia at Augusta University

Public Release: 21-Apr-2016
Nature Biotechnology
Infectious outbreaks must be combatted strategically, Dartmouth-HHS experts argue
New funding is not enough to guarantee success against emerging infectious diseases around the world. Rather, good governance, a long-term technology investment strategy and strong product management skills are essential, say a Dartmouth College researcher and her co-author.

Contact: John Cramer
john.cramer@dartmouth.edu
603-646-9130
Dartmouth College

Public Release: 21-Apr-2016
The Lancet
Reducing infectious malaria parasites in donated blood could help prevent transmission
A technique for reducing the number of infectious malaria parasites in whole blood could significantly reduce the number of cases of transmission of malaria through blood transfusion, according to a collaboration between researchers in Cambridge, UK, and Kumasi, Ghana.
Terumo BCT

Contact: Craig Brierley
craig.brierley@admin.cam.ac.uk
44-012-237-66205
University of Cambridge

Public Release: 20-Apr-2016
eLife
Where next for Zika virus?
A new global risk map reveals priority regions where authorities could intervene to control the vector mosquito population and where surveillance of the virus should be concentrated in order to improve rapid outbreak response and clinical diagnosis.

Contact: Zoe Dunford
z.dunford@elifesciences.org
44-077-863-03597
eLife

Public Release: 20-Apr-2016
Dissertations
Parts of Europe may be exposed to dengue outbreaks
Global travel and climate change increase the risk for epidemics of the mosquito-borne dengue virus, and potentially other climate-sensitive infectious diseases, spreading into temperate areas. This according to a doctoral dissertation at Umeå University in Sweden.

Contact: Daniel Harju
daniel.harju@umu.se
46-725-522-918
Umea University

Public Release: 20-Apr-2016
PLOS ONE
Taking aspirin could increase cancer survival by 20 percent
Patients receiving cancer treatment could increase their chance of survival by up to 20 percent and help stop their cancer from spreading by taking a low dose of aspirin, new research suggests.

Contact: Peter Elwood
Peter.c.elwood@gmail.com
07-837-340-199
Cardiff University

Public Release: 19-Apr-2016
JAMA
Two-vaccine Ebola regimen shows promise in early-stage clinical trial
An immunization regimen using two Ebola vaccine candidates was safe, well-tolerated and induced an immune response in healthy adult volunteers in a Phase 1 clinical trial. Results from the study are described in the April 19th issue of the Journal of the American Medical Association. NIAID has supported the development and testing of the two investigational vaccines: Ad26.ZEBOV, developed by Crucell Holland B.V., and MVA-BN-Filo, developed by Bavarian Nordic.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Jennifer Routh
jennifer.routh@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 19-Apr-2016
PLOS Neglected Tropical Diseases
Scientists describe new research model to enhance Zika virus research
Researchers at the University of Wisconsin-Madison School of Veterinary Medicine have developed one of the first mouse models for the study of Zika virus. The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.

Contact: Matthew Aliota
mtaliota@wisc.edu
608-262-7785
University of Wisconsin-Madison

Public Release: 19-Apr-2016
Association for Chemoreception Sciences (AChemS) 38th Annual Meeting
A small dose of E. coli wall has big impact on the sweet tooth
Putting just a tiny piece of the wall of detoxified E. coli into their gut make mice lose their natural sweet tooth, researchers report.

Contact: Toni Baker
tbaker@augusta.edu
706-721-4421
Medical College of Georgia at Augusta University

Public Release: 19-Apr-2016
PLOS Medicine
Clinical trial for experimental Ebola drug publishes results
Results of the Wellcome Trust funded trial of the experimental anti-Ebola drug TKM-130803 published in PLOS Medicine. Using a novel approach designed to get rapid indications of a drug's effectiveness, the trial showed that at the dose given the drug did not improve survival compared to historic controls.
Wellcome Trust

Contact: Tom Calver
news.office@admin.ox.ac.uk
44-186-527-0046
University of Oxford

Public Release: 19-Apr-2016
JAMA
Study examines safety, immune response of candidate Ebola vaccines
In a study appearing in the April 19, 2016 issue of JAMA, Matthew D. Snape, F.R.C.P.C.H., M.D., of the University of Oxford, United Kingdom, and colleagues conducted a phase 1 trial to evaluate the tolerability and immunogenicity of two candidate Ebola vaccines, an adenovirus type 26 vector vaccine (Ad26.ZEBOV), and a modified Ankara vector vaccine (MVA-BN-Filo).

Contact: Matthew D. Snape, F.R.C.P.C.H., M.D.
matthew.snape@paediatrics.ox.ac.uk
The JAMA Network Journals

Public Release: 19-Apr-2016
Report: Stagnant US funding for tools against disease threats leaves world at serious risk
Even as Congress grapples with the White House on how to fund an emergency response to fight Zika virus, a new report warns that overall underfunding for development of lifesaving tools against neglected global diseases is putting the United States and the world at risk, and that emergency funding can't be allowed to substitute for sustained US investment in research and development (R&D) of global health technologies.

Contact: Katy Lenard
klenard@burness.com
301-280-5719
Global Health Technologies Coalition

Public Release: 18-Apr-2016
Journal of Biological Chemistry
Discovery of enzyme in the sleeping sickness parasite streamlines drug development
Researchers from Umeå University in Sweden have discovered that the single-celled parasite causing African sleeping sickness has a defense mechanism against potential pharmaceuticals under development against the disease. The deadly parasite has an enzyme that can cleave and hence disarm adenosine analogue pharmaceuticals. This according to a study recently published in the Journal of Biological Chemistry.

Contact: Daniel Harju
daniel.harju@umu.se
46-725-522-918
Umea University

Public Release: 18-Apr-2016
New TB clinical trial data-sharing platform available for researchers
C-Path, TDR, TB Alliance, and St. George's, University of London, announce the launch of the TB-Platform for Aggregation of Clinical TB Studies (TB-PACTS): a database designed to catalyze tuberculosis (TB) research by curating and standardizing trial data from the REMoxTB, RIFAQUIN, and OFLOTUB clinical trials, and making them available to researchers. Having these data under one platform helps inform policymaking and drug development, ultimately benefiting TB patients.

Contact: Kissy Black
kissyblack@lotosnile.com
615-310-1894
The Critical Path Institute (C-Path)

Public Release: 18-Apr-2016
American Journal of Tropical Medicine and Hygiene
New study: Significant health impacts from extreme weather linked to climate change in South Pacific
As weather events turn more frequent and more extreme in the 21st century, a new study published today in the American Journal of Tropical Medicine and Hygiene details the public health impacts after devastating flooding on a South Pacific island, and provides graphic evidence of the risk facing island populations and their health systems worldwide. Researchers documented the injury, loss of life, disease, and displacement experienced by the people of Honiara, the Solomon Islands capital city, after torrential rains triggered flash floods in April 2014.

Contact: Bridget DeSimone
bdesimone@burness.com
301-280-5735
Burness

Public Release: 18-Apr-2016
Annals of Internal Medicine
ACP issues urgent call to action to avert major threat to public health
Climate change will have devastating consequences for public and individual health unless aggressive, global action is taken now to curb greenhouse gas emissions, the American College of Physicians says in a new policy paper published today in Annals of Internal Medicine.

Contact: ACP Public Relations Department
215-351-2514
American College of Physicians

Public Release: 14-Apr-2016
Antibiotics may have lasting impact on the immune system of children
Scientists want to know whether taking antibiotics early in life can disrupt your immune system function lifelong. Regardless of our age, antibiotics at least temporarily wipe out many of the good gut bacteria, or microbiota, that help us digest and use food and eliminate waste. That may be particularly problematic for children because, up to about age 3, this useful group of bacteria also is helping educate their immune system about what to ignore and what to attack.
National Institutes of Health

Contact: Toni Baker
tbaker@augusta.edu
706-721-4421
Medical College of Georgia at Augusta University

Public Release: 14-Apr-2016
Wayne State receives $2.5 million NIH grant to shape next generation of antibiotics
Researchers at Wayne State University recently received a $2.5 million grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health for a study that aims to shape the next generation of antibiotics for the treatment of multidrug-resistant diseases.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Julie O'Connor
julie.oconnor@wayne.edu
313-577-8845
Wayne State University - Office of the Vice President for Research

Public Release: 14-Apr-2016
SMFM releases statement on ultrasound screening for fetal microcephaly
The Society for Maternal-Fetal Medicine released a statement on the use of ultrasound screening for fetal microcephaly following Zika virus exposure.

Contact: Vicki Bendure
vicki@bendurepr.com
540-687-3360
Society for Maternal-Fetal Medicine

Public Release: 14-Apr-2016
Global, community leaders launch 'Mental Health Now' (mhNOW) partnership to tackle fast growing need
The Mental Health Now initiative launches at the inaugural Financing and Innovation in Global Health conference, Washington, D.C. Partners are Global Development Incubator, Johnson & Johnson, Grand Challenges Canada (funded by the Government of Canada), BasicNeeds, and StrongMinds. Social entrepreneurs, organizations and companies will unite to create and implement mental health solutions in communities worldwide, improving economic stability through better health. From 1990-2013, people suffering depression and/or anxiety increased ~50 percent, from 416 to 615 million.

Contact: Terry Collins
tc@tca.tc
416-878-8712
Financing and Innovation in Global Health

Public Release: 14-Apr-2016
One of world's leading scientists, Dr. Matthew L. Meyerson, to receive Han-Mo Koo Memorial Award
In recognition of his immeasurable contributions to the understanding of cancer genomics and targeted therapies, Van Andel Research Institute will present renowned scientist Matthew L. Meyerson, M.D., Ph.D., with the 2016 Han-Mo Koo Memorial Award. As part of the award, Meyerson will deliver an educational lecture May 19 and a scientific lecture May 20 at the Institute in Grand Rapids, Mich.

Contact: Beth Hinshaw Hall
beth.hinshawhall@vai.org
616-234-5519
Van Andel Research Institute

Public Release: 14-Apr-2016
PLOS Neglected Tropical Diseases
Trachomatous trichiasis surgery improves quality of life regardless of vision outcomes
Trachomatous trichiasis (TT, inturning of the eyelashes to touch the eye following longterm infection with Chlamydia trachomatis) affects over seven million people world-wide. Corrective eyelid surgery is the recommended treatment for TT. A study published in PLOS Neglected Tropical Diseases reports that surgery substantially increases the quality of life (QoL) for affected people, even when their vision is not improved.
Wellcome Trust

Contact: Esmael Habtamu
esmael.ali@lshtm.ac.uk
44-207-927-2329
PLOS

Public Release: 13-Apr-2016
PLOS ONE
Sugary drinks tax would offer big benefits
A 20 percent tax on sugar-sweetened drinks would result in widespread, long-lasting public health benefits and significant health cost savings, a new study shows.
World Health Organization Collaborating Centre for Obesity Prevention, Obesity Policy Coalition

Contact: Fiona Cameron
f.cameron2@uq.edu.au
61-733-467-086
University of Queensland

Public Release: 13-Apr-2016
Dr. Prabhat Jha receives CIHR Trailblazer Award
The Canadian Institutes of Health Research's Institute of Population and Public Health has awarded Dr. Prabhat Jha its inaugural Trailblazer Award in Population Health Solutions.

Contact: Kendra Stephenson
stephensonk@smh.ca
416-864-5047
St. Michael's Hospital

Showing releases 251-275 out of 1298.

<< < 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 > >>